Evidence mapPaperPMID 24963111Full record

Trial reportDiabetes care2014

Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled study.

Sun H Kim, Alice Liu, Danit Ariel, Fahim Abbasi, Cindy Lamendola, Kaylene Grove, Vanessa Tomasso, Hector Ochoa, Gerald Reaven

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Diabetes care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02285985 (Effects of Saxagliptin on Adipose Tissue Inflammation in Humans), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02285985 phase4completednot on this map

Effects of Saxagliptin on Adipose Tissue Inflammation in Humans

TypeinterventionalSponsorPhoenix VA Health Care SystemRan2013 to 2019Enrolled103ConditionsType 2 Diabetes Mellitus (T2DM)ArmsSaxagliptin, Placebo
3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Targeting Insulin-Degrading Enzyme in Insulin Clearance.International journal of molecular sciences · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sun H KimDepartment of Medicine, Stanford University School of Medicine, Stanford, CA sunhkim@stanford.edu.
Alice LiuDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.
Danit ArielDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.
Fahim AbbasiDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.
Cindy LamendolaDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.
Kaylene GroveDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.
Vanessa TomassoDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.
Hector OchoaDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.
Gerald ReavenDepartment of Medicine, Stanford University School of Medicine, Stanford, CA.

Funding

WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · 2022 to 2025
$5.6M
NCATS NIH HHS KL2 TR001083NIDDK NIH HHS DK-088136NIDDK NIH HHS P30 DK020579NIDDK NIH HHS R01 DK088136
6 · The paper itself

Abstract

objectiveSalsalate treatment has been shown to improve glucose homeostasis, but the mechanism remains unclear. The aim of this study was to evaluate the effect of salsalate treatment on insulin action, secretion, and clearance rate in nondiabetic individuals with insulin resistance. RESEARCH DESIGN AND

methodsThis was a randomized (2:1), single-blind, placebo-controlled study of salsalate (3.5 g daily for 4 weeks) in nondiabetic individuals with insulin resistance. All individuals had measurement of glucose tolerance (75-g oral glucose tolerance test), steady-state plasma glucose (SSPG; insulin suppression test), and insulin secretion and clearance rate (graded-glucose infusion test) before and after treatment.

resultsForty-one individuals were randomized to salsalate (n = 27) and placebo (n = 14). One individual from each group discontinued the study. Salsalate improved fasting (% mean change -7% [95% CI -10 to -14] vs. 1% [-3 to 5], P = 0.005) but not postprandial glucose concentration compared with placebo. Salsalate also lowered fasting triglyceride concentration (-25% [-34 to -15] vs. -6% [-26 to 14], P = 0.04). Salsalate had no effect on SSPG concentration or insulin secretion rate but significantly decreased insulin clearance rate compared with placebo (-23% [-30 to -16] vs. 3% [-10 to 15], P < 0.001). Salsalate was well tolerated, but four individuals needed a dose reduction due to symptoms.

conclusionsSalsalate treatment in nondiabetic, insulin-resistant individuals improved fasting, but not postprandial, glucose and triglyceride concentration. These improvements were associated with a decrease in insulin clearance rate without change in insulin action or insulin secretion.

Indexed as

Insulin ResistanceAdultAnti-Inflammatory Agents, Non-SteroidalBlood GlucoseFastingFemaleGlucose Tolerance TestHumansInsulinInsulin SecretionMaleMiddle AgedPostprandial PeriodSalicylatesSingle-Blind MethodTriglyceridesAnti-Inflammatory Agents, Non-SteroidalBlood GlucoseInsulinSalicylatessalicylsalicylic acidTriglycerides

Identifiers

PMID24963111
PMCPMC4067392

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.